Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic and Pharmacodynamic Evaluation from an Expansion Cohort

The aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic (PK) and pharmacodynamic (PD) markers with clinical outcome. In addition, a novel PD marker based on the real-time measurement of RAF...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Quintela-Fandino, Miguel, Le Tourneau, Christophe, Duran, Ignacio, Chen, Eric X., Wang, Lisa, Tsao, Ming, Bandarchi-Chamkhaleh, Bizhan, Pham, Nhu-Ann, Do, Trevor, MacLean, Martha, Nayyar, Rakesh, Tusche, Michael W., Metser, Ur, Wright, John J., Mak, Tak W., Siu, Lillian L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838726/
https://ncbi.nlm.nih.gov/pubmed/20197396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados